利妥昔单抗生物类似药与参照药治疗类风湿关节炎的真实世界比较
在退伍军人健康管理局(VHA)中,回顾性队列研究比较利妥昔单抗-pvvr与参照药治疗类风湿关节炎(RA)的疗效与安全性。1074例新使用者经熵平衡后分析显示,停用泼尼松的组间风险差为0.05(95%CI -0.04~0.14),感染相关住院或急诊风险差为-0.02(95%CI -0.08~0.05),均无显著差异。
要点
- 利妥昔单抗-pvvr与参照药在RA退伍军人中疗效和安全性无临床意义差异。
- 停用泼尼松风险差0.05(95%CI -0.04~0.14),感染相关住院或急诊风险差-0.02(95%CI -0.08~0.05)。
- 真实世界证据支持RA患者临床使用利妥昔单抗-pvvr。
核心结论
- 在RA新使用者中,利妥昔单抗-pvvr与参照药在疗效和安全性上无临床意义差异,支持生物类似药的临床使用。
研究设计与样本
- 回顾性队列研究,使用VHA药房福利管理数据,纳入2020年3月1日至2023年8月31日期间接受利妥昔单抗参照药或利妥昔单抗-pvvr治疗RA的≥18岁退伍军人。
- 疗效与安全性结局在熵平衡后的新使用参照药与生物类似药亚组中采用回归分析评估。
主要发现
- 研究期间共1717例RA退伍军人接受利妥昔单抗参照药或利妥昔单抗-pvvr治疗。
- 在1074例新使用者中,疗效结局无显著差异,如停用泼尼松的风险差(RD)=0.05,95%CI -0.04~0.14。
- 安全性结局无显著差异,如感染相关住院或急诊就诊的RD=-0.02,95%CI -0.08~0.05。
关键数值与推荐
- 停用泼尼松的风险差(RD)=0.05,95%CI -0.04~0.14。
- 感染相关住院或急诊就诊的风险差(RD)=-0.02,95%CI -0.08~0.05。
临床怎么用
- 对于适合利妥昔单抗治疗的RA患者,可考虑使用利妥昔单抗-pvvr,其疗效与安全性与参照药相当。
- 该真实世界证据有助于提高临床医生和患者对生物类似药采用的信心。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Real-world comparisons of rituximab biosimilars with originator rituximab have largely focused on oncology, with limited evidence in RA. This gap is particularly pertinent to the Veterans Health Administration (VHA), where patients with RA are older and have greater comorbidity. We evaluated the effectiveness and safety of rituximab-pvvr vs originator rituximab in veterans with RA by (i) describing treatment patterns, (ii) assessing effectiveness, (iii) evaluating adverse events and (iv) identifying reasons for switching back to the originator after initiating the biosimilar. METHODS: We conducted a retrospective cohort study using VHA Pharmacy Benefits Management data among veterans aged ≥18 years who received originator rituximab or rituximab-pvvr for RA between 1 March 2020 and 31 August 2023. Effectiveness outcomes (e.g. prednisone use) and safety outcomes (e.g. infection) were assessed using regression analyses within entropy-balanced subgroups of incident originator and biosimilar users. RESULTS: A total of 1717 veterans with RA received originator rituximab or rituximab-pvvr during the study period. Among 1074 incident users, there were no significant differences between originator and biosimilar groups in effectiveness [e.g. discontinued prednisone use: risk difference (RD) = 0.05; 95% CI -0.04-0.14] or safety (e.g. infection-related hospitalizations or emergency department visits: RD = -0.02; 95% CI -0.08-0.05). CONCLUSION: We found no clinically meaningful differences in the effectiveness or safety of rituximab-pvvr compared with originator rituximab among incident users with RA. These real-world findings support the clinical use of rituximab-pvvr and may improve clinician and patient confidence in biosimilar adoption.
引用
- Ghassemi S, Singh JA, Jiang R, et al. Effectiveness and safety of rituximab-pvvr versus originator rituximab for rheumatoid arthritis in the Veterans Health Administration. Rheumatology (Oxford). 2026. PMID: 42568143. doi:10.1093/rheumatology/keag406
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。